← boardnext 2026-12next 2027-02next 2027-03next 2027-08next 2027-09next 2027-09next 2029-08next 2030-12
IONS
Ionis Pharmaceuticals, Inc.distress 2/10 · well-funded / low risk$55.85+3%today-35% from 52w high
Hematology 1
Lead: Alexander disease · target Prekallikrein
Revenue
$246M
Liquidity
$1919M
Runway
2.1 yrs
Shares 1y
+4%
Price & events
-31.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
+3.4%
1D
+2.2%
1W
-26.5%
1M
-24.6%
3M
-30.4%
6M
+31.8%
1Y
+10.7%
2Y
+46.9%
5Y
-1.6%
All
Overview
- Market Cap
- $9.23B
- Enterprise Value
- $10.38B
- Volume
- 241.39K
- 52 Week Range
- $40.69 – $86.50
- Total Shares
- 165.26M
- Float Shares
- 163.96M
- Short %
- 13.99%
- % Held by Insiders
- 0.61%
- % Held by Institutions
- 107.36%
- RVOL
- 0.07x
- Beta
- 0.36
Pipeline stages · 9 programs
Donidalorsen
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ION717
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Olezarsen
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ION582
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ION775
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ION440
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Eplontersen
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ION337
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
sapablursen
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 15 trials · 13 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2027-02-14 | Phase 3 | Donidalorsen | Hereditary Angioedema | — | active not recruiting |
| 2027-02 Estimated 50% readout ~2027-03-18 | Phase 1/2 | ION717 | Prion Disease | — | recruiting |
| 2027-03 Estimated 50% readout ~2027-05-15 | Phase 3 | Olezarsen | Severe Hypertriglyceridemia | — | active not recruiting |
| 2027-06 Estimated 50% readout ~2027-08-15 | Phase 3 | Olezarsen | Familial Chylomicronemia Syndrome | — | active not recruiting |
| 2027-08 Estimated 50% readout ~2027-10-15 | Phase 3 | ION582 | Angelman Syndrome | — | recruiting |
Show all 15 trials · 10 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-09 Estimated 50% readout ~2027-10-16 | Phase 2 | ION775 | Hypertriglyceridemia, Severe Hypertriglyceridemia | — | recruiting |
| 2027-09 Estimated 50% readout ~2027-10-16 | Phase 1/2 | ION440 | Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome | — | recruiting |
| 2028-02 Estimated 50% readout ~2028-04-16 | Phase 3 | Olezarsen | Familial Chylomicronemia Syndrome | — | active not recruiting |
| 2029-03 Estimated 50% readout ~2029-04-15 | Phase 1/2 | ION582 | Angelman Syndrome | — | recruiting |
| 2029-06 Estimated 50% readout ~2029-08-15 | Phase 3 | Donidalorsen | Hereditary Angioedema (HAE) | — | recruiting |
| 2029-08 Estimated 50% readout ~2029-10-15 | Phase 3 | Eplontersen | Hereditary Transthyretin-Mediated Amyloid Polyneuropathy | — | active not recruiting |
| 2029-08 Estimated 50% readout ~2029-10-15 | Phase 3 | Eplontersen | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) | — | enrolling by invitation |
| 2030-12 Estimated 50% readout ~2031-01-15 | Phase 1/2 | ION337 | Dravet Syndrome | — | recruiting |
| 2025-06-26 | Phase 2 | sapablursen | Phlebotomy Dependent Polycythemia Vera | 50 | active not recruiting |
| 2025-01-24 | Phase 2 | Donidalorsen | Hereditary Angioedema | 20 | completed |
Upcoming readouts & decisions · our signals
2 upcoming events have our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 16
- 2026Guided 40%PDUFAPDUFAolezarsen · PDUFA target action date in 2026SEC 8-K
- 2026readoutPhase 3WAINUA · Phase 3 readout for WAINUA in ATTR-CMSEC 8-K
- Q3 2026Guided 70%PDUFAPDUFAbepirovirsen · First regulatory decisions anticipatedSEC 8-K
- Prescription Drug User Fee Act action date of September 22, 2026Confirmed 100%PDUFAPDUFAzilganersen · FDA PDUFA action date set.SEC 8-K
- August 2026conferencedata presentationsecondaryPhase 3eplontersen · Full CARDIO-TTRansform results at European Society of Cardiology CongressSEC 8-K
- 2026-07-29Estimated 45%earningsEarningsEarnings releaseyahoo
- today at the 2026 American Academy of Neurology annual meetingconferencedata presentationsecondaryPhase 3zilganersen · Presented additional positive results from pivotal study at AAN 2026.SEC 8-K
- from Q1 2026regulatory submissionFiled (NDA/BLA)bepirovirsen · Global regulatory filings plannedSEC 8-K
- Q1 2026regulatory submissionFiled (NDA/BLA)zilganersen · Plan to submit NDA to FDASEC 8-K
- by end of yearregulatory submissionFiled (NDA/BLA)olezarsen · sNDA submission to FDA plannedSEC 8-K
- 2025readoutPhase 3olezarsen · Phase 3 readout for olezarsen in sHTGSEC 8-K
- Q3 2025readoutPhase 3olezarsen · Data from pivotal Phase 3 CORE and CORE2 studies evaluating olezarsen for sHTGSEC 8-K
- 2024regulatory submissionFiled (NDA/BLA)olezarsen · Submit MAA for olezarsen in Europe in 2024SEC 8-K
- second half of 2024chmp opinionCHMP (EU)WAINUA · EMA decision on WAINUA for ATTRv-PNSEC 8-K
- December 19, 2024PDUFAPDUFAolezarsen · PDUFA date for olezarsen for FCSSEC 8-K
- 2024-02-01withdrawalTEGSEDI · Initiated withdrawal of TEGSEDI NDA in the USSEC 8-K
Approved drugs (2)
- DAWNZERA (AUTOINJECTOR)DONIDALORSEN SODIUM2025 · Prescription
- TRYNGOLZA (AUTOINJECTOR)OLEZARSEN SODIUM2024 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $93 (+66% upside) · 20 analysts
- 2026-07-21GuggenheimBuy
- 2026-07-16Wolfe ResearchOutperform → Peer Perform
- 2026-07-13RBC CapitalOutperform
- 2026-07-10HC Wainwright & Co.Buy
- 2026-07-10Morgan StanleyOverweight
- 2026-07-10BarclaysOverweight
Competitors — Prekallikrein
- none identified
Recent news
- 2026-07-23Canaccord reiterates Ionis stock rating on Tryngolza advantage By Investing.com - Investing.com Canada
- 2026-07-22Earnings Preview: Ionis Pharmaceuticals (IONS) Q2 Earnings Expected to Decline - Yahoo Finance
- 2026-07-22Ionis Pharmaceuticals, Inc. (IONS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
- 2026-07-22Ionis Pharmaceuticals, Inc. (IONS) Shows Oversold Potential with Low RSI - GuruFocus
- 2026-07-21Ionis Pharmaceuticals Under Investigation for Securities Fraud - Intellectia AI
- 2026-07-21Ionis Pharmaceuticals, Inc. (IONS) Shows Oversold Potential with Low RSI - GuruFocus
- 2026-07-21Ionis Pharmaceuticals Stock Slides 39% Over 9 Straight Down Days - Trefis
- 2026-07-20Bronstein, Gewirtz & Grossman, LLC Is Investigating Ionis Pharmaceuticals, Inc. (IONS) And Encourages Investors to Connect - ACCESS Newswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.